Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences receives EU approval for hepatitis C therapy Vosevi

Gilead Sciences receives EU approval for hepatitis C therapy Vosevi

8th August 2017

Gilead Sciences has announced that its drug Vosevi has been approved in Europe for the treatment of all genotypes of chronic hepatitis C.

The European Commission has granted marketing authorisation for Vosevi – a once-daily single tablet regimen combining sofosbuvir, velpatasvir and voxilaprevir – for the treatment of adults with genotype 1 to 6 chronic hepatitis C virus infections.

It is the first and only single-tablet regimen for patients who have previously failed therapy with direct-acting antivirals.

Dr John Milligan, Gilead's president and chief executive officer, said: "We look forward to working with healthcare providers and governments to ensure Vosevi is made available to patients who would benefit the most from it."

Additionally, the company has received an approval for an extension of the marketing authorisation for Harvoni, which was previously authorised for the treatment of adults with chronic hepatitis genotypes 1, 3, 4, 5 or 6.

The drug can now also be used in adolescents aged 12 to 18 years, making it the first direct-acting antiviral regimen to receive EU marketing authorisation for use in an adolescent population.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801838712-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.